Generics - Oncology, Research

Filter

Current filters:

OncologyResearch

Popular Filters

Pharmstandard commits $30 million to Argos Therapeutics; post 1st-half results

28-08-2013

Russia's largest drugmaker Pharmstandard (PHST: RU) that its subsidiary Pharmstandard International.(Luxembourg)…

AGS-003Argos TherapeuticsFinancialGenericsOncologyPharmaceuticalPharmstandardResearch

BPH drug doesn't increase risk of death, but does save men from prostate cancer

15-08-2013

A long-term follow-up to a groundbreaking study led by the director of the Cancer Therapy & Research…

finasterideGenericsMen's HealthMerck & CoOncologyPharmaceuticalProscarResearch

US firms establish strategic partnership around biosimilars

06-08-2013

Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Hospira's biosimilar epoetin meets primary endpoints in post-marketing study

04-06-2013

Leading provider of injectable drugs and infusion technologies Hospira (NYSE: HSP) says that results…

BiotechnologyepoetinGenericsOncologyResearchRetacrit

Briefs: Ablynx inks research deal with Spirogen; Solent Pharma debuts

25-02-2013

Belgium drug developer Ablynx (Euronext Brussels: ABLX]) has entered into a research collaboration with…

AblynxGenericsidebenoneIdecortexLicensingMarkets & MarketingNeurologicalOncologyPharmaceuticalResearchSolent PharmaSpirogen

ScinoPharm and Foresee Pharma set up JV for novel oncological peptide drugs

31-01-2013

Taiwanese drugmaker ScinoPharm (TWSE: 1789) and Foresee Pharmaceuticals, a Delaware, USA-based spin-out…

Asia-PacificForesee PharmaceuticalsGenericsleuprolideOncologyPharmaceuticalProductionResearchScinoPharm

Pfizer links with SFJ Pharma for dacomitinib trial; settles with Mylan

10-09-2012

SFJ Pharmaceuticals Group, a global drug development group of companies which provides a unique co-development…

dacomitinibDetrol LAGastro-intestinalsGenericsLegalMylan LaboratoriesNorth AmericaOncologyPatentsPfizerPharmaceuticalResearchSFJ Pharmaceuticals

AstraZeneca drops early-stage obesity drug; Roche loses out on Indian Tarceva dispute

10-09-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has told its development partner Palatin Technologies…

Asia-PacificAstraZenecaCiplaErlocipGenericsMetabolicsOncologyPalatin TechnologiesPatentsPharmaceuticalResearchRocheTarceva

Merck KGaA collaborates with Dr Reddy's on biosimilars

07-06-2012

With the aim of capitalizing on the batch of patent expires for blockbuster biotechnology-based drugs…

BiotechnologyDr Reddy's LaboratoriesGenericsMarkets & MarketingMerck KGaAMerck SeronoOncologyResearch

Sandoz initiates two more Phase III biosimilar trials

20-01-2012

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), says that it has initiated two milestone…

AmgenBiotechnologyFilgrastimGenericsNovartisOncologypegfilgrastimResearchSandozZarzio

Hospira progresses biosimilar Epogen

11-01-2012

USA-based Hospira (NYSE: HSP), a leading provider of generic injectable drugs and infusion technologies,…

AmgenBiotechnologyEpogenerythropoietinGenericsHospiraNephrology and HepatologyOncologyResearch

Glycotope enrolls first patient for “biobetter” of Roche cancer drug Herceptin

20-09-2011

Berlin, Germany-based glycomics specialist Glycotope GmbH says it has enrolled the first patients in…

BiotechnologyGenericsGlycotopeHerceptinOncologyResearchRochetrastuzumab

Teva ups stake in CureTech to 75% following positive clinical results in lymphoma

14-09-2011

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says it is exercising its option to make an…

CureTechGenericsMergers & AcquisitionsOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

Company Spotlight

ImmunoGen

ImmunoGen

Back to top